Plasma IL-17A levels in patients with late-life depression
| Autor: | Antônio Lúcio Teixeira, Smita Saraykar, Mariana de Souza Nicolau, Lucelia Scarabeli Silva Barroso, Jéssica Diniz Rodrigues Ferreira, Laiss Bertola, Kelly Silva Pereira, Érica Leandro Marciano Vieira, Natalia S. Dias, Ana Paula Mendes Silva, Breno S. Diniz, Bo Cao |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty lcsh:RC435-571 Population Brief Communication immunology 03 medical and health sciences 0302 clinical medicine Internal medicine lcsh:Psychiatry medicine Humans education Depression (differential diagnoses) Aged cognitive impairment education.field_of_study Depressive Disorder Major business.industry Depression Interleukin-17 Case-control study Neuropsychology Cognition Late life depression medicine.disease cytokines 030227 psychiatry Psychiatry and Mental health Case-Control Studies Mann–Whitney U test Major depressive disorder Female business 030217 neurology & neurosurgery Biomarkers |
| Zdroj: | Brazilian Journal of Psychiatry, Iss 0 (2017) Brazilian Journal of Psychiatry Revista Brasileira de Psiquiatria, Issue: ahead, Published: 19 OCT 2017 Revista Brasileira de Psiquiatria, Volume: 40, Issue: 2, Pages: 212-215, Published: 19 OCT 2017 Brazilian Journal of Psychiatry v.40 n.2 2018 Brazilian Journal of Psychiatry (São Paulo. 1999. Online) Associação Brasileira de Psiquiatria (ABP) instacron:ABP |
| Popis: | Objective: A consistent body of research has confirmed that patients with major depressive disorder (MDD) have increased concentrations of pro-inflammatory cytokines, including IL-6, TNF-α, IL-1β, the soluble IL-2 receptor, and C-reactive protein, compared to controls; however, there is limited information on IL-17A in MDD. Moreover, information about IL-17A in older populations, i.e., patients with late-life depression (LLD), is conspicuously missing from the literature. The purpose of this study was to investigate the role of IL-17A in LLD. Methods: A convenience sample of 129 individuals, 74 with LLD and 55 non-depressed controls, were enrolled in this study. The Mann-Whitney U test was used to compare plasma IL-17A levels between LLD and controls subjects, and Spearman’s rank order correlation was used to investigate correlation of these levels with clinical, neuropsychological, and cognitive assessments. Results: Plasma IL-17A levels were not statistically different between LLD patients and controls (p = 0.94). Among all subjects (LLD + control), plasma IL-17A did not correlate significantly with depressive symptoms (rho = -0.009, p = 0.92) but a significant correlation was observed with cognitive assessments (rho = 0.22, p = 0.01). Conclusion: Our findings do not support an association between plasma IL-17A levels and LLD. Nevertheless, IL-17A may be associated with cognitive impairment in LLD patients. If this finding is confirmed in future longitudinal studies, modulation of the T-helper 17 cell (Th17) immune response may be a treatment target for cognitive impairment in this population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|